ClinConnect ClinConnect Logo
Search / Trial NCT06871215

Inflammation and Infective Endocarditis

Launched by BARTS & THE LONDON NHS TRUST · Mar 5, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Endocarditis Transcatheter Valve Congenital

ClinConnect Summary

This clinical trial is studying a serious heart condition called infective endocarditis (IE), which occurs when bacteria enter the bloodstream and attach to heart valves, causing damage. The researchers believe that the immune system may be overactive in these patients, potentially worsening the condition by attacking the heart itself. They want to find out if certain immune cells in the blood and valve tissue can help identify patients who have an autoimmune response related to IE. This information could lead to new treatments that help manage the disease more effectively.

To participate in the trial, individuals must have a confirmed diagnosis of infective endocarditis based on specific medical criteria. Unfortunately, those currently dealing with active cancer cannot join. Participants will undergo tests to analyze their immune cells, which may involve a blood sample and tissue taken during surgery. The study is not yet recruiting, but it aims to improve understanding and treatment options for people affected by this serious illness.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • A clinical diagnosis of infective endocarditis according to the Duke Criteria.
  • Exclusion Criteria:
  • Active solid organ or haematological malignancy.

About Barts & The London Nhs Trust

Barts and The London NHS Trust is a leading healthcare organization in the United Kingdom, renowned for its commitment to delivering high-quality clinical care, research, and education. As a prominent sponsor of clinical trials, the Trust is dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. With a focus on patient safety and ethical standards, Barts and The London NHS Trust collaborates with multidisciplinary teams to explore cutting-edge therapies and interventions across various medical fields, ensuring that trial participants receive the highest level of care and support throughout their involvement.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Federica Marelli-Berg, MD PhD

Study Director

Queen Mary University of London

Simon Woldman, MD

Study Director

Barts & The London NHS Trust

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported